Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer ...
CAMBRIDGE, Mass., Sept. 30, 2025 /PRNewswire/ -- Clear Scientific Inc., a clinical stage biopharmaceutical company focused on the development of first-in-class small molecules to reverse acute ...
WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する